Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bulevirtide - MYR Pharma

Next Previous
Drug Profile

Bulevirtide - MYR Pharma

Alternative Names: 915207G; GS-4438; HEPCLUDEX; Hepcludex; MyrB; Myrcludex; Myrcludex-B; Myrcludex-B-MYR Pharma

Latest Information Update: 03 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; University of Heidelberg
  • Developer Hepatera; MYR Pharma
  • Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hepatitis D
  • Phase II Hepatitis B
  • No development reported Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 28 Jul 2025 Launched for Hepatitis D in Denmark (SC)
  • 07 May 2025 Efficacy and adverse events data from a phase III MYR301 trial in Hepatitis D presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)
  • 07 May 2025 Efficacy data from a phase III MYR301 trial in Hepatitis D presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top